https://doi.org/10.55788/e95820e1
Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis Next Article
High potential for secukinumab as next biologic treatment for HS »
« Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis Next Article
High potential for secukinumab as next biologic treatment for HS »
Table of Contents: EADV 2022
Featured articles
Letter from the Editor
Psoriasis and Psoriatic Arthritis: What You Need to Know
Novel oral psoriasis drug maintains efficacy over 2 years
A3 adenosine receptor agonist showed modest efficacy but excellent tolerability
Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA
AI machine learning algorithm useful in early detection of PsA
Novel Developments in Sun Protection
Myths regarding “health benefit” of suntan prevail in majority of population
Fern extract reverses severe actinic keratosis lesions
Vitiligo in 2022
Enhancing re-pigmentation rates with topical ruxolitinib in all body areas
Markedly lower skin cancer risk in vitiligo patients
Pruritus Treatment: Novel Agents Entering the Arena
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis
Nalbuphine: aspiring to become another treatment for prurigo nodularis?
Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy?
Pharmacotherapy in Hidradenitis Suppurativa: New Opportunities
High potential for secukinumab as next biologic treatment for HS
Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise
Best of The Posters
High rate of non- or partial responders jeopardises therapeutic success in HS
Genital psoriasis: high prevalence, often underdiagnosed
Decreased overall survival in melanoma patients with low vitamin D
News in Atopic and Seborrheic Dermatitis
Baricitinib possible therapeutic option for children with AD
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD
Does 8 weeks of emollients use prevent AD in high-risk infants?
Roflumilast foam led to high response rates in seborrheic dermatitis
What Is Hot in Hair Disorders?
Long-term improvement in alopecia areata with ritlecitinib therapy
Topical gel plus finasteride beneficial for patients with androgenetic alopecia
Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata
Related Articles
November 5, 2022
Long-term improvement in alopecia areata with ritlecitinib therapy
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy